James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2016 American Medical Association. This is an author produced version of a paper subsequently published in JAMA Oncology. Uploaded in accordance with the publisher's self-archiving policy. |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 13 Jul 2016 15:53 |
Last Modified: | 14 Apr 2017 03:38 |
Published Version: | http://dx.doi.org/10.1001/jamaoncol.2015.5570 |
Status: | Published |
Publisher: | American Medical Association |
Refereed: | Yes |
Identification Number: | 10.1001/jamaoncol.2015.5570 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:101667 |